Exhibit 5.1

Yaakov Neeman z"l*

Tuvia Erlich

Meir Linzen

Alan Sacks

Yaacov Brandt

Ehud Sol

Janet Levy Pahima

Yael Bar-Shai

Yaacov Sharvit

David Zailer

Mark Phillips

Adam Eytan

Orly Gerbi

Moshe Hardi

Gilad Wekselman

Yossi Ashkenazi

Gil White

Anthony Leibler

Eldad Chamam

Ilanit Landesman Yogev

Limor Hodir

Ory Nacht

Esther Sternbach

Ariel Flavian

Nati Simchony

Roni Libster

Karen L. Elburg

Hanan Haviv

Roy Nachimzon

Liat Shaked-Katz

Ruth Dagan

Asher Dovev

Odelia Offer

Sharon Petel

Moria Tam-Harshoshanim

Guy Katz

Daniel Reisner

Nurit Dagan

Yaniv Dinovitch

Nir Raber

Harriet Finn

Ofir Segev

Ran Hai

Haya Ehrman

Tal Dror Schwimmer

Shai Kagan

Chagai Vered

Gilad Majerowicz

Yuval Navot

Michal Caspi

Shira Margalit -Elbaz

Efri Berkovich

Yehoshua Shohat Gurtler

Shachar Porat

Amir Peres

Yair Geva

Nir Dash

Itzhak Shragay

Tamara Tapoohi Waldman

Hanna Bilavsky

Saar Pauker

Orit Hipsher

Moshe Yaacov

Daniel Lipman Lowbeer

Neil Wilkof

Nimrod Kozlovski

Moran Yemini

Ofer Granot

Ron Ben-Menachem

Dan Sharot

Ronen Hausirer

Gilad Neeman

Ayelet Regavim K.

Ariel Yosefi

Natalie Jacobs

Roi Hayun

Eyal Bar-Zvi

Yariv Ben-Dov

Talya Solomon

Haim Machluf

Yuval Meidar

Aviram Hazak

Itai Sarfaty

Ran Kedem

Ra'anan Sagi

Revital Katz

Tal Hamdi

Neta Dorfman-Raviv

Yuval Zilber

Vladi Borodovsky

Gal Schwartz

Assaf Klein

Hen Tirosh

Racheli Pry-Reichman

Ifat Pagis-Gelman

Yael Chervinsky Edan

Maayan Hammer-Tzeelon

Adina Shapiro

Tsouriel Picard

Itay Lavi

Eran Wagner

Dana Zur-Neumann

Gal Eschet

Zohar Yahalom

Galia Kleinman

Inbal Altman

Iris Weinberger

Yoni Frider

Lev Zigman

Uriel Mozes

Elad Wieder

Liran Barak

Efrat Tzur

Chen Moyal

Abigail Borowitz

Niv Sivan

Asaf Nahum

Ehab Farah

Iris Achmon

Orli Gal

Limor Shechter Lerner

Chen Luzzatto

Ohad Elkeslassy

Adar Bengom Ortal

Liat Maidler

Nir Miller

Tomer Farkash

Roni Cohen Pavon

Mark Goldman

Zara Gold

Natan Wiesenberg

Yael Hauser

Hagit Oren

Ruth Bergwerk

Robert Wiseman

Israel (Ruly) Ber

Avital A. Shlomovich

Michal Haberfeld

Zeev Kallach

Keren Assaf

Yaniv Grossman

Nir Gal

Michal Lavi

Chen Ginon Cohen

David Preyl

Dana Kashi

Avishay Klein

Moran Ninio Nesher

Yotam Blaushild

Boaz Nahshoni

Michal Dolev (Pereg)

Maor Roth

Rosie Mordoch-Ron

Rani Hirsh

Ilana Zibenberg

Guy Yekutiel

Shahar Fishbein

Pini Duek

Sahar Regev

Jenia Melkhior

Karin Fried

Yehonatan Ohayon

Lital Wolfovitz

Reut Alcalay

Aviv Parienty

Rafael Herbst

Sarit Shainboim

Ido Manor

Shiran Shouldiner

Dafna Amster Kahn

Liya Friedman

Esti Hadar

Pini Shriki Herstic

Zvika Friedman

Ella Corren

Liron Tzur Neumann

Marian Fertleman

Itamar Gur

Yehuda Hommfor

Amit Laufer

Talia Blazer

Einat Steiner

Tom Waltner

Yoav Sananes

Alon Abcasis

Asaf Beker

Eitan Ella

Noa Leon

Grigory Danovich

Eliran Doyev

Orr Diskin

Daniel Paz

Gal Sagi

Sharbel Shama

Erez Abu

Hofit Cahana

Gilad Eshed

Uriya Gehasi

Zecharia Rechtschaffen

Nitzan Schindler

Harel Elazar

Liran Ben Asuly

Batell Vallentine Blaish

Dana Baranes

Asaf Bar Natan

Elina Shechter

Neil Hadad

Anat Tsur

Rachel Rinberg-Shuri

*Founding Partner

April 2, 2018

To:

Foamix Pharmaceuticals Ltd.

2 Holzman Street, Weizmann Science Park

Rehovot, 7670402

Israel

Re: Registration Statement on Form S-3

Ladies and Gentlemen:

We have acted as Israeli counsel for Foamix Pharmaceuticals Ltd., an Israeli company (the “Company”), in connection with the registration statement on Form S-3 (the “Registration Statement”), filed herewith by the Company with the United States Securities and Exchange Commission (the “SEC”), pursuant to the United States Securities Act of 1933, as amended (the “Securities Act”), which registers the offer, issuance and sale by the Company, from time to time, of up to $291,936,389, in the aggregate, of ordinary shares, par value NIS 0.16 per share of the Company (the “Shares”).

This opinion letter is rendered pursuant to Item 16 of Form S-3 promulgated by the SEC and Items 601(b)(5) and (b)(23) of the SEC’s Regulation S-K promulgated under the Securities Act.

In connection herewith, we have examined the originals, photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the draft of the Registration Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the articles of association of the Company, as amended and restated and currently in effect (the “Articles”); (iii) minutes of a meeting or written consents of the board of directors of the Company (the “Board”) at which the filing of the Registration Statement and the actions to be taken in connection therewith were approved; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. We have also assumed the truth of all facts communicated to us by the Company and that all minutes of meetings of the Board that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws.

Assuming (a) the taking of all necessary corporate action to authorize and approve the issuance of any Shares, the terms of the offering thereof and related matters (the “Authorizing Resolutions”), (b) the effectiveness (without termination or rescindment) of the Registration Statement, as finally amended (including any post-effective amendments), under the Securities Act, (c) the delivery and filing of an appropriate prospectus supplement with respect to the offering of the Shares in compliance with the Securities Act and the applicable rules and regulations thereunder, (d) approval by the Board of, and entry by the Company into, and performance by the Company under, any applicable underwriting agreement, any post-effective amendment thereto or to a report on Form 8-K, pursuant to which the Shares may be issued and sold, and (e) receipt by the Company of the consideration for the Shares as provided for in the Authorizing Resolutions and in accordance with the provisions of any such underwriting agreement, if any, pursuant to which the Shares may be issued, such Shares will be validly issued, fully paid and non-assessable.

You have informed us that you intend to issue the Shares from time to time on a delayed or continuous basis, and this opinion is limited to the laws, including the rules and regulations, as in effect on the date hereof.

Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.

We consent to the filing of this opinion as an exhibit to the Company’s Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC’s Regulation S-K under the Securities Act.

This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.

Very truly yours,

/s/ Herzog Fox & Neeman